BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 28675905)

  • 1. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
    Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
    Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
    Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
    Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
    Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
    Li CY; Huang PM; Chu PY; Chen PM; Lin MW; Kuo SW; Lee JM
    Biomed Res Int; 2016; 2016():6423297. PubMed ID: 27777949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma.
    Hsu PK; Huang CS; Wang BY; Wu YC; Hsu WH
    Ann Thorac Surg; 2014 May; 97(5):1734-41. PubMed ID: 24612702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis.
    Hsu HY; Chao YK; Hsieh CH; Wen YW; Chang HK; Tseng CK; Liu YH
    Ann Thorac Surg; 2016 Nov; 102(5):1687-1693. PubMed ID: 27457831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
    Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
    Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
    Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
    Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.
    Tapias LF; Mathisen DJ; Wright CD; Wain JC; Gaissert HA; Muniappan A; Lanuti M; Donahue DM; Morse CR
    Ann Thorac Surg; 2016 Mar; 101(3):1097-103. PubMed ID: 26652140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node volume predicts survival in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery.
    Pao TH; Chen YY; Chang WL; Wu SY; Lai WW; Tseng YL; Chung TJ; Lin FC
    PLoS One; 2024; 19(3):e0300173. PubMed ID: 38547184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
    Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-modality treatment in patients with advanced stage tonsil cancer.
    Roden DF; Schreiber D; Givi B
    Cancer; 2017 Sep; 123(17):3269-3276. PubMed ID: 28440876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
    Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K; Beitler JJ; Shin DM; Willingham FF; El-Rayes B; Landry JC; Fernandez FG; Saba NF
    Cancer; 2017 Sep; 123(18):3476-3485. PubMed ID: 28464264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the causes of failure after radical surgery in patients with
    Shen WB; Gao HM; Zhu SC; Li YM; Li SG; Xu JR
    World J Surg Oncol; 2017 Oct; 15(1):192. PubMed ID: 29070049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Yamakita I; Kurokawa T; Okada M
    Ann Thorac Surg; 2016 Oct; 102(4):1132-9. PubMed ID: 27319990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer.
    Ji KSY; Thomas SM; Roman SA; Czito B; Anderson KL; Frakes J; Adam MA; Sosa JA; Robinson TJ
    J Gastrointest Surg; 2019 May; 23(5):885-894. PubMed ID: 30374818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.